Pomerantz Law Firm Issues Securities Class Action Deadlines for Four Firms

The landscape of securities litigation has intensified with the Pomerantz Law Firm issuing a series of critical reminders for investors regarding class action lawsuits against four distinct entities: Ultragenyx Pharmaceutical Inc. (RARE), Fermi Inc. (FRMI), Mereo BioPharma Group plc (MREO), and Navan, Inc. (NAVN). These alerts, all issued on March 5, 2026, signal a coordinated legal push against companies in the high-growth biotechnology and technology sectors, where disclosure accuracy and clinical trial transparency are frequently the subjects of intense regulatory and legal scrutiny.

For the biotechnology firms involved—Ultragenyx and Mereo BioPharma—the litigation typically centers on the communication of clinical trial data or the regulatory approval pathway for orphan drugs and rare disease treatments. Ultragenyx, a leader in the rare disease space, and Mereo, which focuses on oncology and rare respiratory diseases, operate in a high-stakes environment where a single data point can swing market capitalization by billions. Allegations in such cases often involve the purported failure to disclose adverse events, setbacks in FDA communications, or the overstatement of a drug's commercial viability. For investors, these lawsuits represent a secondary layer of risk beyond the inherent scientific uncertainty of drug development.

“

The landscape of securities litigation has intensified with the Pomerantz Law Firm issuing a series of critical reminders for investors regarding class action lawsuits against four distinct entities: Ultragenyx Pharmaceutical Inc.

Navan, Inc. and Fermi Inc. represent the technology and industrial-tech side of this legal wave. Navan, formerly known as TripActions, has transitioned into a major player in corporate travel and expense management. Securities litigation in this sector often revolves around growth metrics, the sustainability of revenue models, or disclosures made during or following an initial public offering (IPO). Fermi Inc., likely operating in the advanced technology or energy sectors, faces similar pressures regarding the transparency of its operational milestones. The common thread across these tech-focused suits is the allegation that management provided a 'materially false or misleading' outlook that artificially inflated stock prices before a corrective disclosure led to significant investor losses.

The role of the Pomerantz Law Firm in these proceedings is significant. As one of the premier firms specializing in corporate, securities, and antitrust class action litigation, Pomerantz has a long history of recovering billions for investors. Their strategy of issuing these 'reminders' is designed to consolidate the class and identify a lead plaintiff—typically the investor with the largest financial interest—who will oversee the litigation on behalf of the group. Under the Private Securities Litigation Reform Act (PSLRA), the selection of the lead plaintiff is a critical early milestone that dictates the direction and potential settlement leverage of the case.